A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

112 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a trial of dexanabinol in patients with advanced tumours. The purposes of the protocol are to study different doses of the study drug to determine the maximum safe dose of the drug given in combination with standard chemotherapies and to further understand the safety of the study drug and to measure any reduction in size of patients' cancer tumour(s).

Dexanabinol is a synthetic cannabinoid which has previously undergone clinical trials for traumatic brain injury (TBI) and in subjects undergoing coronary artery bypass surgery. Currently dexanabinol is under investigation for potential anti-tumour activity in patients with advanced tumours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT00550901

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

NCT04891289

Intrahepatic Cholangiocarcinoma

RECRUITING PHASE2

Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer

NCT00004220

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor

NCT00004243

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Scheduling Nab-paclitaxel With Gemcitabine

NCT03529175

Pancreatic Adenocarcinoma Metastatic

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Relapsed or refractory advanced tumours

Patients with selected relapsed or refractory tumour types to receive single agent dexanabinol.

Group Type EXPERIMENTAL

Dexanabinol

Intervention Type DRUG

Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period

Newly diagnosed hepatocellular carcinoma

Patients with hepatocellular carcinoma to receive dexanabinol in combination with standard chemotherapy.

Group Type EXPERIMENTAL

Dexanabinol

Intervention Type DRUG

Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period

Sorafenib

Intervention Type DRUG

Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)

Newly diagnosed pancreatic cancer

Patients with pancreatic cancer to receive dexanabinol in combination with standard chemotherapy

Group Type EXPERIMENTAL

Dexanabinol

Intervention Type DRUG

Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period

Nab-paclitaxel

Intervention Type DRUG

Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion

Gemcitabine

Intervention Type DRUG

Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexanabinol

Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period

Intervention Type DRUG

Sorafenib

Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)

Intervention Type DRUG

Nab-paclitaxel

Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion

Intervention Type DRUG

Gemcitabine

Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ETS2101 HU-211

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. (i) Parts 1 and 2b (dexanabinol combination): Patients with selected histologically, cytologically or radiologically confirmed tumours that are advanced, metastatic and/or progressive, and eligible for 1st line chemotherapy.

* HCC only: patient with Child-Pugh A stage.
* Pancreatic cancer only: patients diagnosed with adenocarcinoma (i.e. pancreatic cancer patients with islet cell neuroplasms are excluded).

(ii) Part 2a (dexanabinol monotherapy): Patients with histologically, cytologically or radioloigically confirmed tumours that are advanced, metastatic and/or progressive, for whom there is no effective standard therapy available.
* Pancreatic cancer only: patients diagnosed with adenocarinoma (i.e. pancreatic cancer patients with islet cell neuroplasms are excluded).
2. Adults patients defined by age ≥ 18 years.
3. Eastern Collaborative Oncology Group (ECOG) Performance Status (PS) or 0 or 1.
4. Any acute or chronic adverse effects of prior chemotherapy or radiotherapy have resolved to \< Grade 2 as determined by CTCAE v4.03 criteria, with the exception of alopecia.
5. (i) Parts 1 and 2b: Measureable disease assessed by appropriate method for each tumour type e.g. RECIST 1.1 (Eisenhauer, et al. 2009).

(ii) Part 2a: Evaluable disease, either measureable on imaging, or with informative tumour marker(s).
6. Laboratory values at Screening:

* Absolute neutrophil count ≥ 1.5 x 109L;
* Platelets ≥ 100 x 109/L;
* Total bilirubin; in 1st line pancreatic cancer (part 1 and 2b) ≤1.25 times the upper limit of normal (ULN); all other tumour types and settings except HCC ≤1.5 times ULN; in HCC ≤5 times the ULN
* AST (SGOT) ≤2.5 times the ULN (when there is no liver tumour involvement) up to

* 5 times the ULN (in patients with liver tumour involvement);
* ALT (SGPT) ≤2.5 times the ULN (when there is no liver tumour involvement) up to

* 5 times the ULN (in patients with liver tumour involvement);
* Estimated GFR of \>50 mL/min (based on the Wright formula (Wright, et al. 2001 ); and
* Negative hCG test in women of childbearing potential
7. Have a life expectancy of \>3 months.
8. Ability to give written, informed consent prior to any study-specific Screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.
9. Be willing and able to comply with the study protocol procedures.

Exclusion Criteria

1. Patient is pregnant or breast feeding.
2. History of clinically significant cardiac condition, including ischemic cardiac event, myocardial infarction or unstable cardiac disease within 3 months of Cycle 1, Day 1.
3. Known brain metastases.
4. (i) Parts 1 and 2b (dexanabinol combination): Prior systemic chemotherapy.

(ii) Part 2a (dexanabinol monotherapy): Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to Cycle 1, Day 1 for solid tumours (with the exception of hydroxyurea, which must be discontinued at least 24 hours prior to Cycle 1, Day 1). Localised palliative radiotherapy is permitted for symptom control.
5. Major surgery within 4 weeks prior to Cycle 1, Day 1; bone marrow transplant within 100 days prior to Cycle 1, Day 1.
6. Known human immunodeficiency virus positivity.
7. Active hepatitis B or C or other active liver disease (other than malignancy) (applies to all tumours types enrolled except HCC).
8. Use of any investigational agents within 4 weeks of Cycle 1, Day 1.
9. Any active, clinically significant, viral, bacterial, or systemic fungal infection within 4 weeks prior to Cycle 1, Day 1.
10. History of significant chronic or recurrent infections requiring treatment or any uncontrolled intercurrent illness that would jeopardize patient safety, interfere with the objectives of the protocol, or limit patient compliance with study requirements, as determined by the Investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No